Discovery of Two Clinical Histamine H 3 Receptor Antagonists: trans - N -Ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and trans -3-Fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]- N -(2-methylpropyl)cyclobutanecarboxamide (PF-03654764)
Travis T. Wager, Betty A. Pettersen, Anne W. Schmidt et al. · Journal of Medicinal Chemistry · 2011
The discovery of two histamine H(3) antagonist clinical candidates is disclosed. The pathway to identification of the two clinical candidates, 6 (PF-03654746) and 7 (PF-03654764) required five hypothesis driven design cycles. The key to success in identifying these clinical candidates was the development of a compound design strategy that leveraged medicinal chemistry knowledge and traditional assays in conjunction with computational and in vitro safety tools. Overall, clinical compounds 6 and 7 exceeded conservative safety margins and possessed optimal pharmacological and pharmacokinetic profiles, thus achieving our initial goal of identifying compounds with fully aligned oral drug attributes, "best-in-class" molecules.
Cited by 109 works. doi:10.1021/jm200939b
Authors
- Travis T. Wager
- Betty A. Pettersen
- Anne W. Schmidt
- Douglas K. Spracklin
- Scot Mente
- Todd W. Butler
- Harry R Howard
- Daniel J. Lettiere
- David M. Rubitski
- Diane F. Wong
- Frank M. Nedza
- Hans Rollema
- Jeffrey W. Raggon
- Jiri Aubrecht
- Jody Freeman
- John M. Marcek
- Julie A. Cianfrogna
- Karen W. Cook
References
- Definition and Antagonism of Histamine H2-receptors
- Molecular Properties That Influence the Oral Bioavailability of Drug Candidates
- RECEPTORS MEDIATING SOME ACTIONS OF HISTAMINE
- Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties
- Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor
- A Comparison of Physiochemical Property Profiles of Development and Marketed Oral Drugs
- Physiochemical drug properties associated with in vivo toxicological outcomes
- The impact of drug-induced QT interval prolongation on drug discovery and development
- Medicinal chemical properties of successful central nervous system drugs
- Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties